FDA Expands Talazoparib Combo Indication in Prostate Cancer Amy Norton

https://www.medscape.com/viewarticle/fda-expands-talazoparib-combo-indication-prostate-cancer-2026a10014gv?src= The FDA has approved the PARP inhibitor talazoparib (Talzenna, Pfizer) in combination with enzalutamide for the treatment of patients with metastatic androgen pathway modulation-naive or -sensitive (mAPMN/S) prostate cancer with homologous recombination repair (HRR) gene mutations, as detected by an FDA-authorized test. The regimen was first approved by the FDA in 2023, for patients with HRR gene-mutated metastatic castration-resistant prostate cancer.